share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SciSparc | 6-K:外國發行人報告
美股SEC公告 ·  2024/09/26 21:22

Moomoo AI 已提取核心訊息

SciSparc Ltd. has signed a non-binding letter of intent to divest its 52.73% ownership stake in MitoCareX Bio Ltd. to a US-listed company. The transaction will occur in two phases: first, a $700,000 cash payment for 27% ownership, followed by share-based compensation for the remaining 73% stake, valuing MitoCareX at $5 million.The deal includes potential milestone-based payments that could increase the total consideration from $5 million to $7 million. The proposed valuation represents a 47% increase from SciSparc's initial $3.4 million investment in MitoCareX, which focuses on developing cancer therapeutics targeting mitochondrial SLC25 protein family.The transaction's final terms remain subject to definitive agreements. Notable governance overlaps exist, with SciSparc's board chairman Amitay Weiss and director Liat Sidi also serving on the purchaser's board.
SciSparc Ltd. has signed a non-binding letter of intent to divest its 52.73% ownership stake in MitoCareX Bio Ltd. to a US-listed company. The transaction will occur in two phases: first, a $700,000 cash payment for 27% ownership, followed by share-based compensation for the remaining 73% stake, valuing MitoCareX at $5 million.The deal includes potential milestone-based payments that could increase the total consideration from $5 million to $7 million. The proposed valuation represents a 47% increase from SciSparc's initial $3.4 million investment in MitoCareX, which focuses on developing cancer therapeutics targeting mitochondrial SLC25 protein family.The transaction's final terms remain subject to definitive agreements. Notable governance overlaps exist, with SciSparc's board chairman Amitay Weiss and director Liat Sidi also serving on the purchaser's board.
SciSparc有限公司已簽署一份非約束性的意向書,計劃將其在MitoCareX Bio有限公司52.73%的股權出售給一家美國上市公司。該交易將分兩個階段進行:首先支付70萬美元現金以獲得27%股權,然後通過基於股份的補償獲得剩餘73%的股份,使MitoCareX的估值達到500萬美元。該交易包括潛在的里程碑支付,這可能將總對價從500萬美元提高到700萬美元。建議的估值較SciSparc最初在MitoCareX投資的340萬美元提高了47%,後者專注於開發針對線粒體SLC25蛋白家族的癌症治療藥物。該交易的最終條款仍需依賴於最終協議的確定。值得注意的是,SciSparc董事會主席Amitay Weiss和董事Liat Sidi也在買方的董事會任職,存在顯著的治理重疊。
SciSparc有限公司已簽署一份非約束性的意向書,計劃將其在MitoCareX Bio有限公司52.73%的股權出售給一家美國上市公司。該交易將分兩個階段進行:首先支付70萬美元現金以獲得27%股權,然後通過基於股份的補償獲得剩餘73%的股份,使MitoCareX的估值達到500萬美元。該交易包括潛在的里程碑支付,這可能將總對價從500萬美元提高到700萬美元。建議的估值較SciSparc最初在MitoCareX投資的340萬美元提高了47%,後者專注於開發針對線粒體SLC25蛋白家族的癌症治療藥物。該交易的最終條款仍需依賴於最終協議的確定。值得注意的是,SciSparc董事會主席Amitay Weiss和董事Liat Sidi也在買方的董事會任職,存在顯著的治理重疊。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息